Philip Morris International
PM
$194.86
+1.99%
Philip Morris International Inc. is a global tobacco and nicotine company that sells combustible cigarettes alongside a growing portfolio of reduced-risk products, including IQOS heated tobacco, Zyn nicotine pouches, Veev vapes, and Swedish Match oral tobacco, operating primarily outside the United States. PMI is the undisputed global leader in heated tobacco and, following the 2023 Swedish Match acquisition, has become a dominant force in the fast-growing U.S. nicotine pouch category, giving it a dual-platform identity as both a cash-generative cigarette incumbent and a smoke-free disruptor. The current investor narrative centers on the accelerating smoke-free transition, with reduced-risk products now contributing roughly 43% of quarterly revenue ($4.38 billion of $10.15 billion in Q1 2026), and on the durability of Zyn's U.S. growth amid intensifying FDA scrutiny of nicotine pouches and rising competition from Turning Point Brands and Altria. Bulls argue PMI's pricing power, 3.5% dividend yield, and Zyn/IQOS momentum justify a premium multiple, while bears point to regulatory overhang, a deeply negative equity position, and decelerating headline growth as reasons for caution.…
PM
Philip Morris International
$194.86
Related headlines
Investment Opinion: Should I buy PM Today?
The synthesized recommendation is Buy, anchored by a consensus analyst rating of Buy (mean 1.69) and an average target price of $207.27, implying 8.5% upside from the current price of $191.06. The core thesis is that PMI's smoke-free transition is accelerating, with reduced-risk products now 43% of revenue and growing double digits, which justifies a premium multiple and provides a durable growth engine. The 3.46% dividend yield and low beta of 0.395 make it an attractive holding for income-oriented and defensive investors.
Supporting evidence includes revenue growth of 9.09% YoY in Q1 2026, gross margin expansion to 68.06% from 67.32%, and a net margin of 24.03%. Free cash flow of $10.67 billion comfortably covers the dividend, and the PEG ratio of 0.365 suggests the stock is inexpensive relative to its earnings growth trajectory. The forward PE of 20.84x represents a 30-45% premium to the tobacco sector's forward average of 14-16x, but this is defensible given PMI's superior growth and margin profile. The implied upside to the average analyst target is 8.5%, with the high target of $230.00 offering 20.4% upside if smoke-free momentum accelerates.
The biggest risks that could invalidate the thesis are FDA regulatory setbacks on nicotine pouches, decelerating smoke-free growth below 10%, and a broader de-rating of consumer staples. The rating would upgrade to a stronger Buy if Zyn and IQOS growth accelerates above 15% and the FDA provides a favorable regulatory framework, or downgrade to Hold if revenue growth decelerates below 5% or if the forward PE expands above 25x without commensurate earnings growth. Relative to its own history, the current PE of 22.06x is near the middle of its 15.3x-29.3x range, and relative to peers, it trades at a premium that is justified by superior fundamentals; the stock appears fairly valued with a slight upside bias.
Sign up to view all
PM 12-Month Price Forecast
PMI presents a compelling bullish case driven by its accelerating smoke-free transition, with reduced-risk products now 43% of revenue and growing double digits. The company's exceptional profitability, with a 38.37% operating margin and $10.67 billion in TTM free cash flow, supports both the dividend and debt servicing despite a negative equity position. The consensus analyst target of $207.27 implies 8.5% upside, and the low PEG ratio of 0.365 suggests the stock is undervalued relative to its growth. However, the premium valuation and regulatory risks surrounding nicotine pouches warrant a medium confidence level. I would upgrade to high confidence if the FDA provides a favorable regulatory decision and Zyn growth accelerates above 15%, or downgrade to neutral if revenue growth decelerates below 5% or if regulatory headwinds intensify.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Philip Morris International's 12-month outlook, with a consensus price target around $207.27 and implied upside of +6.4% versus the current price.
Average Target
$207.27
0 analysts
Implied Upside
+6.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$175 - $230
Analyst target range
PMI is covered by 15 analysts, with a consensus recommendation of "Buy" and a recommendation mean of 1.69 (where 1.0 is a Strong Buy and 5.0 is a Sell), indicating a moderately bullish stance. The average price target is $207.27, which implies approximately 8.5% upside from the current price of $191.06. The consensus leans bullish, supported by recent institutional actions: Morgan Stanley maintained Overweight on June 3, 2026, Needham reiterated Buy on April 23, 2026, and Stifel and Citigroup both have Buy ratings, while UBS remains Neutral and Jefferies downgraded from Buy to Hold on January 20, 2026. The distribution of ratings is skewed toward the buy side, with the majority of covering firms positive on the smoke-free transition story. The target price range spans from a low of $175.00 to a high of $230.00, a spread of $55 or roughly 31% of the low target, which signals moderate-to-high uncertainty about the company's trajectory. The high target of $230.00 implies about 20.4% upside and likely assumes accelerating Zyn and IQOS adoption, successful FDA navigation on nicotine pouches, and multiple expansion toward the upper end of PMI's historical PE band. The low target of $175.00 implies about 8.4% downside and likely prices in regulatory setbacks, margin compression from competitive pressure in pouches, or a broader consumer staples de-rating. The estimated EPS average of $12.05 for the forward year, with a range of $11.81 to $12.46, suggests analysts expect roughly 8-10% earnings growth, consistent with the forward PE compression. The relatively tight EPS estimate range (5.5% spread) indicates strong conviction in near-term earnings, even as the wider price target range reflects longer-term strategic uncertainty around regulation and competition.
Drowning in data?
Find the real signal!
Bulls vs Bears: PM Investment Factors
The bull case for PM rests on the accelerating smoke-free transition, with reduced-risk products now 43% of revenue and growing double digits, supported by exceptional 68.06% gross margins and $10.67 billion in TTM free cash flow. The bear case centers on a deeply negative equity position, regulatory risks surrounding Zyn and nicotine pouches, and a premium valuation that leaves little margin for error. Currently, the bull evidence appears stronger: revenue growth of 9.09% YoY, a consensus Buy rating, and 8.5% upside to the average analyst target of $207.27 outweigh the balance sheet concerns, which are mitigated by robust cash generation. The single most important tension is whether Zyn and IQOS can sustain double-digit growth as cigarette volumes decline and FDA scrutiny intensifies; if smoke-free growth decelerates below 10%, the premium multiple would likely compress toward the sector average, significantly altering the thesis.
Bullish
- Smoke-free mix now 43% of revenue: Reduced-risk products generated $4.38 billion of Q1 2026's $10.15 billion revenue, up from a minority contribution just a few years ago. This mix shift is the primary driver of PMI's premium valuation and supports gross margin expansion to 68.06% from 67.32% a year ago.
- Revenue growth accelerating at 9.09% YoY: Q1 2026 revenue of $10.15 billion grew 9.09% over Q1 2025's $9.30 billion, well above the low-single-digit growth typical of mature tobacco peers. The multi-quarter trend shows a stable $10-11 billion quarterly run-rate with no signs of demand destruction.
- Exceptional profitability with 38.37% operating margin: Q1 2026 operating income was $3.89 billion on a 38.37% operating margin, and net income of $2.44 billion represented a 24.03% net margin. These margins are among the highest in consumer staples and reflect strong pricing power and a favorable product mix.
- Free cash flow of $10.67 billion covers dividend: TTM free cash flow of $10.67 billion comfortably covers the $2.30 billion quarterly dividend, even with a 76% payout ratio. Q4 2025 alone generated $4.27 billion in FCF, demonstrating the cash-generative nature of the business.
Bearish
- Deeply negative equity of -$4.89 debt-to-equity: The balance sheet shows a debt-to-equity ratio of -4.89 due to an accumulated deficit from years of buybacks and dividends exceeding earnings. This negative equity position limits financial flexibility and could constrain future capital returns if refinancing conditions tighten.
- Regulatory overhang on nicotine pouches: The FDA's nicotine pouch decision and intensifying scrutiny of Zyn represent a material regulatory risk. Recent news highlights that Turning Point Brands' growth hinges on nicotine pouches, but FDA rules and big tobacco competition could squeeze market share, directly affecting PMI's fastest-growing segment.
- Premium valuation leaves little room for error: PM trades at a trailing PE of 22.06x and forward PE of 20.84x, a 30-45% premium to the tobacco sector's forward average of 14-16x. The PS ratio of 6.14x is elevated for consumer staples, meaning any execution miss could trigger multiple compression.
- Decelerating momentum and relative underperformance: While PM is up 19.19% YTD, its 6-month relative strength versus SPY is -6.01 percentage points, indicating it lagged during the mid-year risk-on phase. The 1-month gain of 2.62% and 3-month gain of 3.67% both trail the 6-month gain of 9.39%, suggesting the sharpest rally is behind it.
PM Technical Analysis
PM is in a sustained uptrend, with the stock up 13.79% over the past year and 19.19% year-to-date, and the current price of $191.06 sits at approximately 74.5% of its 52-week range (low of $142.11, high of $207.76). That positioning signals healthy momentum without being pinned at the highs, leaving room for further upside before the stock becomes technically overextended. The 52-week high of $207.76 remains about 8.7% above the current price, while the low of $142.11 is roughly 25.6% below, framing an asymmetric setup where the trend structure favors the bulls. Recent momentum is constructive but moderating: the stock is up 2.62% over the past month and 3.67% over three months, both trailing the 9.39% six-month gain, indicating the sharpest leg of the rally occurred in the spring. Notably, PM's 1-month relative strength versus SPY is +3.68 percentage points (PM +2.62% vs. SPY -1.06%), a clear sign of defensive rotation into the name, even as the 6-month relative strength of -6.01 points shows PM lagged the broader market during the mid-year risk-on phase. This divergence suggests PM is being treated as a safe-haven, low-beta holding rather than a high-growth momentum vehicle. Key technical support rests at the 52-week low of $142.11, with intermediate support near the $180-182 zone where the stock consolidated in August; resistance is anchored at the 52-week high of $207.76, and a breakout above that level would confirm a new leg higher and likely invite momentum buyers. A breakdown below $180 would signal a loss of the recent uptrend and put the $160-165 area in play. With a beta of just 0.395, PM is roughly 60% less volatile than the S&P 500, meaning position sizing can be larger for equivalent risk budget, but also that the stock will likely underperform in strong bull markets and outperform in risk-off environments.
Beta
0.40
0.40x market volatility
Max Drawdown
-19.3%
Largest decline past year
52-Week Range
$142-$208
Price range past year
Annual Return
+17.3%
Cumulative gain past year
| Period | PM Return | S&P 500 |
|---|---|---|
| 1m | +2.3% | -2.0% |
| 3m | +5.9% | +1.4% |
| 6m | +17.3% | +15.0% |
| 1y | +17.3% | +15.7% |
| ytd | +21.6% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PM Fundamental Analysis
PMI's revenue trajectory remains solidly positive, with Q1 2026 revenue of $10.15 billion representing 9.09% year-over-year growth over Q1 2025's $9.30 billion. The multi-quarter trend shows sequential stability: revenue was $10.36 billion in Q4 2025, $10.85 billion in Q3 2025, and $10.14 billion in Q2 2025, indicating a business running at a consistent $10-11 billion quarterly pace with modest seasonal variation. Segment data reveals the engine of growth: reduced-risk products generated $4.38 billion (43% of revenue) versus $5.77 billion from combustible products, meaning the smoke-free portfolio is now nearly half the business and is the primary driver of the company's premium valuation. The investment case hinges on whether IQOS and Zyn can sustain double-digit growth as cigarette volumes decline, and so far the mix shift is working in PMI's favor. Profitability is robust: Q1 2026 net income was $2.44 billion on a 24.03% net margin, with gross margin of 68.06% and operating margin of 38.37%, both expanding from year-ago levels (Q1 2025 gross margin was 67.32%). The company has now posted positive net income for five consecutive quarters after a Q4 2024 loss of $579 million tied to one-time charges, and the Q1 2026 net income of $2.44 billion was up 9.4% from $2.69 billion in Q1 2025 on a comparable basis. These margins are exceptional for the consumer staples sector and reflect PMI's pricing power and the higher-margin mix of reduced-risk products. The balance sheet is the key risk: debt-to-equity is deeply negative at -4.89 due to an accumulated deficit from years of buybacks and dividends exceeding earnings, and the current ratio of 0.958 indicates current liabilities slightly exceed current assets. However, free cash flow tells a more reassuring story: TTM FCF is $10.67 billion, and the company generated $4.27 billion in Q4 2025 alone, easily covering the $2.30 billion quarterly dividend. The payout ratio of 76% is elevated but manageable given the cash generation, and ROA of 14.59% demonstrates efficient asset utilization despite the negative equity. The main financial risk is the reliance on debt markets to refinance obligations, but with interest coverage of 16.4x in Q1 2026, the company has ample capacity to service its debt.
Quarterly Revenue
$10.1B
2026-03
Revenue YoY Growth
+9.1%
YoY Comparison
Gross Margin
68.1%
Latest Quarter
Free Cash Flow
$10.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PM Overvalued?
Because PMI is profitable with trailing net income of $2.44 billion in Q1 2026 and positive EPS, the PE ratio is the appropriate primary metric. The stock trades at a trailing PE of 22.06x and a forward PE of 20.84x, with the modest 5.5% compression between the two implying the market expects only moderate earnings growth over the next twelve months. The PEG ratio of 0.365 is notably low, suggesting that when growth is factored in, PMI looks inexpensive relative to its earnings expansion trajectory. On a price-to-sales basis, PM trades at 6.14x, which is elevated for a consumer staples company but reflects the market's willingness to pay up for the smoke-free growth story. Relative to the broader Tobacco industry, PMI's trailing PE of 22.06x represents a premium to the sector average, which typically ranges in the mid-teens for mature cigarette names like Altria. The premium is justified by PMI's superior growth profile (9.09% revenue growth vs. low-single-digit for peers), higher gross margins (68.06% vs. industry average in the 55-60% range), and its leadership in the two fastest-growing nicotine categories, heated tobacco and pouches. The forward PE of 20.84x versus the sector's forward average of roughly 14-16x implies a 30-45% premium, which is defensible given PMI's growth and margin advantages but leaves little room for execution missteps. Historically, PMI's PE has ranged from a low of about 15.3x (Q3 2024) to a high of 29.3x (Q4 2025), with the current 22.06x sitting near the middle of that band. The PS ratio of 6.14x is more telling: it is well below the 25.5x recorded in Q1 2026 on a different calculation basis but above the 16-19x range seen throughout 2022-2024, suggesting the market is pricing in sustained smoke-free momentum. At 22x earnings, PMI is neither cheap nor expensive relative to its own history, but the low PEG ratio and 3.46% dividend yield provide a margin of safety for income-oriented investors.
PE
22.1x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 15x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are dominated by PMI's deeply negative equity position, with a debt-to-equity ratio of -4.89 and a current ratio of 0.958, meaning current liabilities exceed current assets. The company carries significant debt from years of buybacks and dividends exceeding earnings, and while interest coverage of 16.4x and TTM free cash flow of $10.67 billion provide ample servicing capacity, refinancing risk remains if credit markets tighten. The 76% dividend payout ratio is elevated, and any earnings volatility—such as the Q4 2024 loss of $579 million from one-time charges—could pressure the company's ability to maintain both the dividend and debt reduction. Additionally, revenue concentration in combustible products ($5.77 billion, or 57% of Q1 2026 revenue) means declining cigarette volumes remain a structural headwind that could offset smoke-free growth.
Market and competitive risks include valuation compression if PMI's premium multiple of 22.06x trailing PE and 20.84x forward PE fails to be justified by growth. The tobacco sector trades at a forward average of 14-16x, so PMI commands a 30-45% premium that could unwind if smoke-free growth decelerates or if competitors like Altria and Turning Point Brands gain share in nicotine pouches. Regulatory headwinds are intensifying, as evidenced by the FDA's nicotine pouch decision and recent news questioning whether Turning Point Brands can defend its market share, which signals a more competitive and regulated landscape. With a beta of 0.395, PM is roughly 60% less volatile than the S&P 500, meaning it will likely underperform in strong bull markets and may face sector rotation risk if investors shift toward higher-growth sectors.
In a worst-case scenario, a combination of FDA regulatory setbacks on Zyn, decelerating smoke-free growth, and a broader de-rating of consumer staples could drive PM toward its 52-week low of $142.11, representing a 25.6% decline from the current price of $191.06. The analyst low target of $175.00 implies a more moderate 8.4% downside, but a severe regulatory outcome could push the stock below that level, especially given the negative equity position and reliance on debt markets. Historical max drawdown for PM is -19.26%, suggesting that a decline to the $150-160 range is plausible in a stress scenario. From the current price, investors could lose approximately 25% to the 52-week low, and if the stock breaks below $180 support, the next technical support is at $160-165, representing a 14-16% decline.
FAQ
The most severe risk is regulatory intervention on nicotine pouches, as the FDA's scrutiny of Zyn could lead to restrictions that significantly impact PMI's fastest-growing segment. Financial risks include the deeply negative debt-to-equity ratio of -4.89 and a current ratio of 0.958, which indicate balance sheet fragility and reliance on debt markets. Competitive risks are rising, with Altria and Turning Point Brands intensifying competition in the U.S. pouch market, potentially eroding PMI's market share and pricing power. Macro risks include the stock's low beta of 0.395, which means it may underperform in strong bull markets, and sector rotation risk if investors shift away from defensive staples. These risks are ranked from most to least severe, with regulatory and financial risks being the most immediate threats.
The 12-month forecast includes three scenarios: a bull case with 25% probability targeting $220-230, a base case with 55% probability targeting $200-215, and a bear case with 20% probability targeting $160-175. The base case is most likely, assuming revenue growth remains stable at 7-9% and the FDA does not impose severe restrictions, leading the stock to trade near the analyst average target of $207.27. The bull case requires accelerating smoke-free growth above 15% and a favorable regulatory outcome, while the bear case assumes regulatory setbacks and competitive share loss. The key assumption behind the base case is that PMI's smoke-free transition continues without major disruption, supported by its strong cash flow and dividend.
PM appears fairly valued with a slight upside bias. The trailing PE of 22.06x and forward PE of 20.84x are near the middle of the stock's historical range of 15.3x to 29.3x, and the PEG ratio of 0.365 suggests the stock is inexpensive relative to its earnings growth. However, the PS ratio of 6.14x is elevated for consumer staples, and the forward PE represents a 30-45% premium to the tobacco sector average of 14-16x. This premium is justified by PMI's superior growth profile and higher margins, but it leaves little room for execution missteps. The market is pricing in continued smoke-free momentum, and any deceleration could lead to multiple compression toward the sector average.
From a risk/reward perspective, PM offers a moderately attractive opportunity with 8.5% upside to the average analyst target of $207.27 and a 3.46% dividend yield. The stock trades at a forward PE of 20.84x, a premium to the tobacco sector, but this is supported by 9.09% revenue growth and a 68.06% gross margin. The biggest downside risk is regulatory intervention on nicotine pouches, which could push the stock toward the 52-week low of $142.11, representing a 25.6% decline. For income-oriented investors with a long-term horizon, PM is a good buy at current levels, but for those seeking high growth, the premium valuation and regulatory overhang may limit near-term upside. It is most suitable for investors who can tolerate moderate volatility and seek a blend of income and growth.
PM is best suited for long-term investment, with a suggested minimum holding period of 2-3 years. The company is in a multi-year transition toward smoke-free products, and the full benefits of this shift will take time to materialize. The low beta of 0.395 and 3.46% dividend yield make it an attractive defensive holding for income-focused portfolios, but the premium valuation and regulatory risks mean short-term trading could be volatile. Earnings visibility is moderate, with analysts estimating forward EPS of $12.05 and a tight range of $11.81 to $12.46, suggesting stable near-term performance. Long-term investors can benefit from the secular growth of IQOS and Zyn, while short-term traders may find limited upside due to the stock's low volatility and premium multiple.
